Ren Ji-Hua, Tao Ying, Zhang Zhen-Zhen, Chen Wei-Xian, Cai Xue-Fei, Chen Ke, Ko Ben C B, Song Chun-Li, Ran Long-Kuan, Li Wan-Yu, Huang Ai-Long, Chen Juan
The Second Affiliated Hospital and the Key Laboratory of Molecular Biology of Infectious Diseases designated by the Chinese Ministry of Education, Chongqing Medical University, Chongqing, China.
J Virol. 2014 Mar;88(5):2442-51. doi: 10.1128/JVI.02861-13. Epub 2013 Dec 11.
Chronic hepatitis B virus (HBV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma. Nevertheless, the molecular mechanism of HBV replication remains elusive. SIRT1 is a class III histone deacetylase that is a structure component of the HBV cccDNA minichromosome. In this study, we found by using microarray-based gene expression profiling analysis that SIRT1 was upregulated in HBV-expressing cells. Gene silencing of SIRT1 significantly inhibited HBV DNA replicative intermediates, 3.5-kb mRNA, and core protein levels. In contrast, the overexpression of SIRT1 augmented HBV replication. Furthermore, SIRT1 enhanced the activity of HBV core promoter by targeting transcription factor AP-1. The c-Jun subunit of AP-1 was bound to the HBV core promoter region, as demonstrated by using a chromatin immunoprecipitation assay. Mutation of AP-1 binding site or knockdown of AP-1 abolished the effect of SIRT1 on HBV replication. Finally, SIRT1 inhibitor sirtinol also suppressed the HBV DNA replicative intermediate, as well as 3.5-kb mRNA. Our study identified a novel host factor, SIRT1, which may facilitate HBV replication in hepatocytes. These data suggest a rationale for the use of SIRT1 inhibitor in the treatment of HBV infection.
慢性乙型肝炎病毒(HBV)感染是肝硬化和肝细胞癌的主要危险因素。然而,HBV复制的分子机制仍不清楚。SIRT1是一种III类组蛋白脱乙酰酶,是HBV共价闭合环状DNA(cccDNA)微型染色体的结构成分。在本研究中,我们通过基于微阵列的基因表达谱分析发现,SIRT1在表达HBV的细胞中上调。SIRT1基因沉默显著抑制HBV DNA复制中间体、3.5kb mRNA和核心蛋白水平。相反,SIRT1的过表达增强了HBV复制。此外,SIRT1通过靶向转录因子AP-1增强HBV核心启动子的活性。染色质免疫沉淀试验表明,AP-1的c-Jun亚基与HBV核心启动子区域结合。AP-1结合位点的突变或AP-1的敲低消除了SIRT1对HBV复制的影响。最后,SIRT1抑制剂sirtinol也抑制了HBV DNA复制中间体以及3.5kb mRNA。我们的研究鉴定了一种新的宿主因子SIRT1,它可能促进HBV在肝细胞中的复制。这些数据为使用SIRT1抑制剂治疗HBV感染提供了理论依据。